Buy Sildenafil (Viagra) online

Buy Viagra (Sildenafil) brand and generic ED drug for erectile dysfunction
Cheap qualitative Sildenafil Citrate 20-800 mg tablets and capsules online



HOW AND WHERE TO BUY SILDENAFIL CITRATE (VIAGRA) 20, 25, 50, 75, 100, 120, 130, 150, 200, 400, 800 MG TABLETS AND CAPSULES ONLINE:

VIAGRA (SILDENAFIL CITRATE): ADVERSE REACTIONS / SIDE EFFECTS

Clinical Trials

Viagra (Sildenafil) tablets were administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated for longer than one year.

In placebo-controlled clinical studies, the discontinuation rate due to adverse events for Viagra (2.5%) was not significantly different from placebo (2.3%). The adverse events were generally transient and mild to moderate in nature.

In trials of all designs, adverse events reported by patients receiving Viagra (Sildenafil Citrate) were generally similar. In fixed-dose studies, the incidence of some adverse events increased with dose. The nature of the adverse events in flexible-dose studies, which more closely reflect the recommended dosage regimen, was similar to that for fixed-dose studies.

When Viagra (Sildenafil Citrate) tablets were taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials, the following adverse events were reported: flushing, headache, dyspepsia, urinary tract infection, nasal congestion, abnormal vision, dizziness, diarrhea, rash.

Other adverse reactions occurred at a rate of > 2%, but equally common on placebo: back pain, respiratory tract infection, flu syndrome, and arthralgia.

In fixed-dose studies, dyspepsia (17%) and abnormal vision (11%) were more common at 100 mg than at lower doses. At doses above the recommended dose range, adverse events were similar to those detailed above but generally were reported more frequently.

The following events occurred in < 2% of patients in controlled clinical trials; a causal relationship to Sildenafil (Viagra) is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful:

Body as a whole: photosensitivity reaction, face edema, shock, pain, asthenia, chills, abdominal pain, accidental fall, allergic reaction, accidental injury, chest pain.

Cardiovascular: AV block, angina pectoris, migraine, tachycardia, syncope, palpitation, postural hypotension, hypotension, myocardial ischemia, cardiac arrest, cerebral thrombosis, heart failure, cardiomyopathy, abnormal electrocardiogram.

Digestive: glossitis, vomiting, colitis, gastritis, dysphagia, gastroenteritis, stomatitis, esophagitis, dry mouth, rectal hemorrhage, liver function tests abnormal, gingivitis.

Hemic and Lymphatic: anemia and leukopenia.

Metabolic and Nutritional: edema, thirst, gout, hyperglycemia, unstable diabetes, peripheral edema, hypoglycemic reaction, hyperuricemia, hypernatremia.

Musculoskeletal: arthrosis, arthritis, myalgia, tenosynovitis, tendon rupture, bone pain, synovitis, myasthenia.

Nervous: hypertonia, ataxia, neuralgia, paresthesia, neuropathy, tremor, depression, vertigo, insomnia, abnormal dreams, somnolence, reflexes decreased, hypesthesia.

Respiratory: dyspnea, asthma, laryngitis, sinusitis, pharyngitis, bronchitis, cough increased, sputum increased.

Skin and Appendages: herpes simplex, urticaria, pruritus, skin ulcer, sweating, contact dermatitis, exfoliative dermatitis.

Special Senses: mydriasis, sudden decrease or loss of hearing, conjunctivitis, tinnitus, photophobia, eye pain, eye hemorrhage, ear pain, cataract, dry eyes.

Urogenital: nocturia, cystitis, urinary frequency, urinary incontinence, breast enlargement, abnormal ejaculation, genital edema and anorgasmia.

Post-Marketing Experience

Cardiovascular and cerebrovascular

Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of Sildenafil (Viagra) tablets. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of Sildenafil Citrate (Viagra) without sexual activity. Others were reported to have occurred hours to days after the use of Sildenafil Citrate (Viagra) tablets and sexual activity. It is not possible to determine whether these events are related directly to Viagra, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors.

Special senses

Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including Viagra (Sildenafil). In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of Viagra (Sildenafil) tablets, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors.

Other events

Other events reported post-marketing to have been observed in temporal association with Viagra (Sildenafil Citrate) and not listed in the clinical trial adverse reactions section above include:

Nervous: seizure recurrence, seizure, anxiety, and transient global amnesia.

Urogenital: priapism, prolonged erection, hematuria.

Special Senses: temporary vision loss/decreased vision, diplopia, ocular redness or bloodshot appearance, ocular swelling/pressure, ocular burning, increased intraocular pressure, vitreous detachment/traction, retinal vascular disease or bleeding, paramacular edema and epistaxis.

Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including Viagra (Sildenafil Citrate) tablets. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient's underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors.

Hemic and Lymphatic: Vaso-occlusive crisis: In a small, prematurely terminated study of Revatio (Sildenafil Citrate) tablets in patients with pulmonary hypertension (PH) secondary to sickle cell disease, vasoocclusive crises requiring hospitalization were more commonly reported in patients who received sildenafil than in those randomized to placebo. The clinical relevance of this finding to men treated with Sildenafil (Viagra) for ED is not known.

Recent posts:

  • Buy Viagra (Sildenafil Citrate) Online
  • Viagra prescribing information

    Copyright © Buy Sildenafil Online